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2014 Cardiovascular Risks Standing Review Panel  
 
Evidence Review for: 
The Risk of Orthostatic Intolerance During Re-Exposure to Gravity 
 
Final Report  
 
 
I.   Executive Summary and Overall Evaluation 
 
The 2014 Cardiovascular Risks Standing Review Panel (from here on referred to as the SRP) 
met for a site visit in Houston, TX on December 17-18, 2014.  The SRP reviewed the updated 
evidence report for The Risk of Orthostatic Intolerance During re-Exposure to Gravity (OI Risk). 
  
The SRP found the 2014 OI Evidence Report to be a well written, comprehensive overview of 
the OI risk; that clearly documents the key scientific evidence relevant for both mechanistic 
understanding and countermeasure development.  The 2014 OI Evidence Report could be further 
strengthened by addressing the points discussed below. 
 
II. Review of the Evidence for the Risk of Orthostatic Intolerance during Re-
Exposure to Gravity  
 
1.  Evaluate the 2014 Orthostatic Intolerance (OI) Evidence Report using the following criteria: 
 
A. Does the 2014 Evidence Report provide sufficient evidence that the Risk is relevant to 
long-term space missions? 
 
Yes, the SRP found that the 2014 OI Evidence Report provides enough evidence that the 
OI Risk is relevant to long-duration space missions. 
 
B. Are the Risk Title and Statement properly stated in the current version of the HRP 
Integrated Research Plan (IRP)?* 
 
Yes, the SRP considers the Risk Title and Statement properly stated. 
 
C. Is the text of the Risk Context provided in the HRP IRP clear? 
 
Yes, the Risk Context text in the HRP IRP is clear. 
 
D. Does the evidence base make the case for the knowledge-type gaps presented? 
 
Yes, the SRP agrees that the evidence base presented in the 2014 OI Evidence Report 
makes the case for the knowledge-type gaps presented. 
 
E. Are there any additional knowledge-type gaps that should be considered for this specific 
Risk? 
 
The SRP recommends additional knowledge-type gaps that should be discussed in the 
2014 OI Evidence Report, including: 
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1) OI on return from microgravity to 1G is common, more severe with longer exposure 
to microgravity, and has potential adverse consequences.  Many years of investigation 
of both return to Earth and head-down bed rest studies have defined the 
epidemiology, mechanisms and countermeasures for OI.  When considering the data 
concerning the incidence of OI following short- and long-duration missions, the SRP 
noted that individuals who were unable to complete orthostatic maneuvers following 
re-exposure to gravity were excluded from the analyses.  It would be helpful to see 
data showing whether they were excluded for technical reasons or if they had such 
severe OI that they could not take part in a stand or tilt test.  In addition, it would be 
helpful to know the atmospheric carbon dioxide (CO2) at landing, since a sudden 
decrease in CO2 can decrease cerebral blood flow (Loveman et al. Diving Hyperb 
Med. 20141). 
 
2) Studies in the past year highlight a new compression garment which shows 
impressive efficacy preventing OI when combined with salt and water loading.  Data 
was not presented by the cardiovascular discipline lead, Dr. Stenger, concerning the 
potential for overheating in astronauts donning and wearing the garment, but it will 
retain heat much less than inflatable garments and is less bulky and lighter.  Members 
of the SRP were impressed with the efficacy of the new compression garment and 
think that some further studies that outline its performance in simulated 3/8 Mars 
gravity and in circumstances that model landing emergencies could further define its 
practical application to spaceflight. 
 
3) Studies on a new compression garment completed in the last year have demonstrated 
impressive efficacy on return from the International Space Station (ISS).  The studies 
have been carried out on astronauts who have ingested about 10 grams of salt in space 
with at least a liter of water.  They then received 1 liter of normal saline prior to 
testing.  Compression garments prevent pooling of blood in the legs and abdomen and 
return blood toward the heart.  Efficacy of the garments depends on the blood volume 
available for compression.  The effect of this new garment on subjects who do not 
have an infusion of saline would be helpful, since saline infusion would not be 
available in an emergency egress. 
 
4) The new compression garment may be so effective that it provides excess 
compression for 3/8 gravity found on Mars.  Studies on the effect of the new garment 
on fluid distribution, blood pressure and heart rate in response to a partial tilt on a tilt 
table could help determine if less compression is appropriate for lower gravitational 
forces.  It is likely that a garment with less compression would be appropriate for 
landing in the lesser gravitational force of Mars. 
 
F. Does the Evidence Report address relevant interactions between this Risk and others in 
the HRP IRP? 
 
The interactions between the OI risk and other risks in the HRP IRP are not specifically 
addressed in the 2014 OI Evidence Report.  A brief synopsis of these interactions would 
be helpful to identify areas where interdisciplinary studies are required. 
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During the 2014 meeting, Dr. Stenger pointed out a number of existing interactions with 
the nutrition lab, the exercise physiology lab, the neurosciences lab, and the visual 
impairment and intracranial pressure (VIIP) team.  Perhaps a section should be added to 
the Evidence Report to discuss these interdisciplinary efforts. 
 
G. Are the qualifications of the author(s) appropriate for identifying the evidence base 
necessary to characterize the given Risk? 
 
Yes, the SRP thinks the team is very knowledgeable, has the appropriate expertise and 
backgrounds to make assessments. 
 
H. Is there information from other HRP disciplines that need to be included in the 2014 
Evidence Report? 
 
As fluid and salt loading are countermeasures for OI, information from the nutrition 
group would seem to be appropriate. 
 
I. Is the breadth of the cited literature sufficient? 
 
Yes, the authors have cited a comprehensive breadth of literature. 
 
J. What is the overall quality and readability of the 2014 Evidence Report? 
 
The 2014 OI Evidence Report is a comprehensive document that provides an excellent 
overview of relevant scientific findings related to the risk of post-flight OI and the 
countermeasures that have been developed and tested to ameliorate OI.  In general, it is a 
well written, scholarly document.  The color-coding in Figure 16 of the 2014 OI 
Evidence Report appears to be incorrect and improvements could be made to a few of the 
figures containing low-magnification, low-resolution images (Figures. 23, 24, 25). 
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IV. 2014 Cardiovascular Risks SRP Evidence Review: Statement of Task for 
the Risk of Orthostatic Intolerance During Re-Exposure to Gravity 
 
In 2008, the Institute of Medicine (IOM) reviewed NASA’s Human Research Program (HRP) 
Evidence Books that describe the Risks that were identified in NASA's Human Research 
Program Requirements Document (PRD).  The 2014 Evidence Report for the Risk of Orthostatic 
Intolerance During Re-Exposure to Gravity (OI) has not been reviewed since the last IOM 
review and there have been significant changes to the evidence base for the Risk. 
 
The 2014 Cardiovascular Risks Standing Review Panel (SRP) is chartered by the Human 
Research Program (HRP) Chief Scientist to review the Evidence Report for the OI Risk.  The 
2014 Cardiovascular Risks SRP will evaluate the Evidence Report and generate a final report of 
your analyses of the evidence base, including any recommendations on how to improve the 
current Evidence Report, and submit it to the HRP Chief Scientist.  Your report will also be 
made available on the Human Research Roadmap (HRR) website. 
 
The 2014 Cardiovascular Risks SRP is charged to: 
 
1. Evaluate the 2014 OI Evidence Report based on each of the following criteria: 
A. Does the 2014 Evidence Report provide sufficient evidence that the Risk is relevant to 
long-term space missions? 
B. Are the Risk Title and Statement properly stated in the current version of the HRP 
Integrated Research Plan (IRP)?* 
C. Is the text of the Risk Context provided in the HRP IRP clear?* 
D. Does the evidence base make the case for the knowledge-type gaps presented? 
E. Are there any additional knowledge-type gaps that should be considered for this specific 
Risk? 
F. Does the Evidence Report address relevant interactions between this Risk and others in 
the HRP IRP? 
G. Are the qualifications of the author(s) appropriate for identifying the evidence base 
necessary to characterize the given Risk? 
H. Is there information from other HRP disciplines that need to be included in the 2014 
Evidence Report? 
I. Is the breadth of the cited literature sufficient? 
J. What is the overall quality and readability of the 2014 Evidence Report? 
 
2. Provide comments on any important issues that are not covered by the criteria in #1 above. 
 
* Please be aware that any suggested changes to the Risk Title, Statement, and Risk Context by the SRP may need to 
be approved by the Human Systems Risk Board (HSRB).  The HSRB has the overall responsibility to implement and 
maintain a consistent, integrated process for assessing, documenting, and tracking all risks to the human system 
associated with spaceflight activities (both in flight and post flight). 
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Additional information regarding this review: 
 
1. Attend a meeting in Houston, TX on December 17 - 18, 2014 to discuss the Evidence Report 
with the Human Health Countermeasures (HHC) Element.  At this meeting, prepare a draft 
report for each risk that addresses each of the evaluation criteria listed in the panel charge (A-
J) including any recommendations on how to improve the Evidence Report.  Debrief the 
HRP Chief Scientist and a representative from the HHC Element on the salient points that 
will be included in the final report and specifically the items in the panel charge. 
 
2. Prepare a draft final report for each risk (within one month of the site visit debrief) that 
contains a detailed evaluation of the Evidence Report specifically addressing items #1 and #2 
of the SRP charge.  The draft final report will be sent to the HRP Chief Scientist and he will 
forward it to the appropriate Element for their review.  The HHC Element and the HRP Chief 
Scientist will review the draft final report and identify any misunderstandings or errors of 
fact and then provide official feedback to the SRP within two weeks of receipt of the draft 
report.  If any misunderstandings or errors of fact are identified, the SRP will be requested to 
address them and finalize the 2014 SRP Final Report as quickly as possible.  The 2014 SRP 
Final Report will be submitted to the HRP Chief Scientist and copies will be provided to the 
HHC Element that sponsors the cardiovascular discipline and also made available to the 
other HRP Elements.  The 2014 SRP Final Report will be made available on the HRR 
website (http://humanresearchroadmap.nasa.gov/). 
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To clarify, the Risk Statement and Risk Context are defined as follows: 
 
Risk Statement: 
“Given the CONDITION, there is a possibility that a CONSEQUENCE will occur”. 
 
Condition:  a single phrase briefly describing current key circumstances, situations, etc. 
that are causing concern, doubt, anxiety, or uncertainty – something that keeps you up at 
night. 
 
Consequence:  a single phrase or sentence that describes the key, negative outcome(s) of 
the current conditions. 
 
Notes:  
The condition-consequence format provides a more complete picture of the Risk, which 
is critical during mitigation planning.  The condition component focuses on what is 
currently causing concern.  This is something that is true or widely perceived to be true.  
This component provides information that is useful when determining how to mitigate a 
Risk. 
 
The consequence component focuses on the intermediate and long-term impact of the 
risk.  Understanding the depth and breadth of the impact is useful in determining how 
much time, resources, and effort should be allocated to the mitigation effort. 
 
A well-formed Risk Statement usually has only one condition, and has one or more 
consequences. 
 
Risk Context: 
Purpose:  provide enough additional information about the Risk to ensure that the original 
intent of the Risk can be understood by other personnel, particularly after time has 
passed. 
 
Description:  capture additional information regarding the circumstances, events, and 
interrelationships not described in the Risk Statement. 
 
An effective context captures the what, when, where, how, and why of the Risk by 
describing the circumstances, contributing factors, and related issues (background and 
additional information that are NOT in the Risk Statement). 
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